Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC- bioautographic assay
- 498 Downloads
Acetylcholinesterase inhibitors (AChEIs) currently form the basis of the newest drugs available for the treatment of Alzheimer’s disease. For the aim of screening effective AChEIs, the methanol extracts of the seeds of genus Peganum were found to show significant inhibitory activity of acetylcholinesterase enzyme (AChE) using an in vitro TLC-bioautographic assay. In further studies to seed of P. nigellastrum Bunge, activity-guided fractionation led to the isolation of two new alkaloids nigellastrine I (9) and nigellastrine II (10), and along with eight known alkaloids, vasicinone (1), vasicine (2), harmine (3), deoxyvasicinone (4), deoxyvasicine (5), harmaline (6), harmol (7), harman (8), in which harmol and harman were first isolated from species P. nigellastrum Bunge. As active constituents, all compounds showed good inhibitory activities against AChE. The results of in vitro semi-quality TLC-bioautographic assay showed that harmine, harmaline and harmol displayed a similar AChE inhibitive activities comparing to galanthamine. These results indicated that these alkaloids in P. nigellastrum Bunge could be a potent class of AChEIs.
Key wordsPeganum nigellastrum Bunge Acetylcholinesterase TLC-bioautographic assay Alzheimer’s disease Alkaloid Nigellastrine I Nigellastrine II
Unable to display preview. Download preview PDF.
- Bores, G. M., Huger, F. P., Petko, W., Mutalib, A. E., Camacho, F., Rush, D. K., Selk, D. E., Wolf, V., Kosley, R. W., Davis, L., and Vargas, H. M., Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther., 277, 728–738 (1996)PubMedGoogle Scholar
- Duan, J. A., Che, C. T., Zhou, R. H., Zhao, S. X., and Wang, M. S., Studies on the chemical constituents of Peganum multisectum Maxim II. Flavonoids and alkaloids from aerial part of plant. J. Chin. Pharm. Univ., 29, 100–104 (1998)Google Scholar
- Duan, J. A., Zhou, R. H., Che, C. T., Wang, M. S., and Zhao, S. X., Studies on the chemicaI constituents of Peganum multisectum Maxim I. The alkaloids from seeds and antitumour activity. J. Chin. Pharm. Univ., 29, 21–23 (1998)Google Scholar
- Glennon, R. A., Dukat, M., Grella, B., Hong, S., Costantino, L., Teitler, M., Smith, C., Egan, C., Davis, K., and Mattson, M. V., Binding of b-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol. Depend., 60, 121–132 (2000)PubMedCrossRefGoogle Scholar
- Ma, J. and Wang, X. L., The species and distribution of genus Peganum in the desert area of China. J. Desert Res., 18, 131–136 (1998)Google Scholar
- Ma, J., and Li, Y. J., A resistant plant to desert: Peganum harmala. Plant Resources 1, 3–4 (1996)Google Scholar
- Pharmacopoeia Commission, Ministry of Pubic Health, 1998. Standard of Uygur drug, Drug Standard of Ministry of Health of the people’s republic of China, Technology & Public Health Press, Xinjiang, pp. 80 (1998)Google Scholar
- Sobhani, A. M., Ebrahimi, S. A., Hoormand, M., Rahbar, N., and Mahmoudian, M., Cytotoxicity of Peganum harmala L. seeds extract and its relationship with contents of β-carboline alkaloids. J. Iran. Un.i Med. Sci., 8, 432–438 (2002)Google Scholar
- Wang, C. H., Liu, J., Zheng, L. M., Lin, Y. M., Zou, X. G., Chen, M., and Sun, D. J., Analysis of harmine and harmaline of Peganum harmala in different parts and different localities. Chin. Pharm. J., 37, 211–215 (2002)Google Scholar